HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board

Preparations for upcoming clinical trials in the USA are ongoing

23-Oct-2024 - HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the appointment of Dr. Martin Bonde as its new Chair of the Board of Directors, effective immediately. His appointment follows the recent €15 million ...

Alzheimer’s Drug PRI-002 Receives EMA Approval for Phase II Trial

27-Nov-2023 - The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase II clinical trial. This is the first time that the drug candidate will be tested on a larger number of Alzheimer’s patients. The drug was ...

CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

Study conducted in Peru and Panama

30-Sep-2020 - CureVac N.V. announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct ...

Atriva announces closing of € 8.6 million oversubscribed convertible loan

Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections

12-Aug-2020 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new ...

Merck initiates clinical Covid-19 study

First clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of Covid-19 infection

26-Jun-2020 - Merck announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 ...

Allergy Vaccine Successful

27-Jan-2017 - Biomay announced that a second Phase IIb study has been successfully completed with its third generation grass pollen allergy vaccine BM32. The study was designed to demonstrate the optimal dose regimen to induce an allergen-specific IgG immune response. Correlation of the immunological effects ...

BioInvent reports clinical hold on BI-505 phase II study

09-Nov-2016 - BioInvent International has received verbal notice from the U.S. Food and Drug Administration that a full clinical hold (i.e. no further dosing of patients) has been placed on BioInvent’s current clinical Phase II study with the antibody BI-505 in patients with multiple myeloma. BioInvent has not ...

Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure

10-Nov-2015 - Mihai Gheorghiade, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues randomly assigned 456 patients with worsening chronic HF and reduced left ventricular ejection fraction to receive placebo or 1 of 4 daily target doses of the medication vericiguat for 12 ...

Invion completes clinical trial of INV103 (ALA-CPN10) in lupus patients

19-Aug-2015 - Invion Limited has completed its Phase II clinical trial entitled “Double-blinded, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and biochemical activity of intravenous Cpn10 administration in subjects with SLE (NCT01838694)”.The Company’s ...

Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Meets Primary Endpoint

19-Aug-2015 - AbbVie announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achievingoverall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review ...